Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Personalized therapy for pancreatic cancer: Myth or reality in 2010?

Literature DB >> 22811802

Personalized therapy for pancreatic cancer: Myth or reality in 2010?

Tzu-Chuan Jane Huang¹, Siddhartha Kar, Milind Javle.

Abstract

Entities: Disease

Year: 2010 PMID： 22811802 PMCID： PMC3397566 DOI： 10.3978/j.issn.2078-6891.2010.009

Source DB: PubMed Journal: J Gastrointest Oncol ISSN： 2078-6891

× No keyword cloud information.

67 in total

1. AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-β-mediated ERK signaling.

Authors: B Kong; C W Michalski; X Hong; N Valkovskaya; S Rieder; I Abiatari; S Streit; M Erkan; I Esposito; H Friess; J Kleeff
Journal: Oncogene Date: 2010-06-28 Impact factor: 9.867

2. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2.

Authors: P N Nair; D T De Armond; M L Adamo; W E Strodel; J W Freeman
Journal: Oncogene Date: 2001-12-13 Impact factor: 9.867

3. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.

Authors: P Ceppi; M Volante; S Novello; I Rapa; K D Danenberg; P V Danenberg; A Cambieri; G Selvaggi; S Saviozzi; R Calogero; M Papotti; G V Scagliotti
Journal: Ann Oncol Date: 2006-09-15 Impact factor: 32.976

4. The role of histological investigation in prognostic evaluation of advanced gastric cancer. Analysis of histological structure and molecular changes compared with invasive pattern and stage.

Authors: A M Chiaravalli; M Cornaggia; D Furlan; C Capella; R Fiocca; G Tagliabue; C Klersy; E Solcia
Journal: Virchows Arch Date: 2001-08 Impact factor: 4.064

5. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).

Authors: Jae Jin Lee; Chi Hoon Maeng; Seon Kyung Baek; Gou Young Kim; Jee-Hong Yoo; Cheon Woong Choi; Yee Hyung Kim; Young-Tae Kwak; Dae-Hyun Kim; Young Kyung Lee; Jung Bo Kim; Si-Young Kim
Journal: Lung Cancer Date: 2010-03-12 Impact factor: 5.705

6. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Authors: Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer
Journal: JAMA Date: 2006-04-12 Impact factor: 56.272

7. Refocusing the war on cancer: the critical role of personalized treatment.

Authors: Anil Potti; Richard L Schilsky; Joseph R Nevins
Journal: Sci Transl Med Date: 2010-04-21 Impact factor: 17.956

8. Screening for epidermal growth factor receptor mutations in lung cancer.

Authors: Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron
Journal: N Engl J Med Date: 2009-08-19 Impact factor: 91.245

9. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer.

Authors: Andrew V Biankin; James G Kench; Emily K Colvin; Davendra Segara; Christopher J Scarlett; Nam Q Nguyen; David K Chang; Adrienne L Morey; C-Soon Lee; Mark Pinese; Samuel C L Kuo; Johana M Susanto; Peter H Cosman; Geoffrey J Lindeman; Jane E Visvader; Tuan V Nguyen; Neil D Merrett; Janindra Warusavitarne; Elizabeth A Musgrove; Susan M Henshall; Robert L Sutherland
Journal: Gastroenterology Date: 2009-04-16 Impact factor: 22.682

Personalized therapy for pancreatic cancer: Myth or reality in 2010?

1. AZGP1 is a tumor suppressor in pancreatic cancer inducing mesenchymal-to-epithelial transdifferentiation by inhibiting TGF-β-mediated ERK signaling.

2. Aberrant expression and activation of insulin-like growth factor-1 receptor (IGF-1R) are mediated by an induction of IGF-1R promoter activity and stabilization of IGF-1R mRNA and contributes to growth factor independence and increased survival of the pancreatic cancer cell line MIA PaCa-2.

3. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.

4. The role of histological investigation in prognostic evaluation of advanced gastric cancer. Analysis of histological structure and molecular changes compared with invasive pattern and stage.

5. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC).

6. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

7. Refocusing the war on cancer: the critical role of personalized treatment.

8. Screening for epidermal growth factor receptor mutations in lung cancer.

9. Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer.

Review 10. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

1. JDP2 inhibits the epithelial-to-mesenchymal transition in pancreatic cancer BxPC3 cells.

2. The effect of JDP2 and ATF2 on the epithelial-mesenchymal transition of human pancreatic cancer cell lines.

3. The therapeutic function of the chemokine RANTES on the H22 hepatoma ascites model.

4. Pancreatobiliary and peripancreatobiliary tuberculosis: a rare cause of obstructive jaundice.